UK markets close in 5 hours 6 minutes
  • FTSE 100

    7,113.40
    +3.43 (+0.05%)
     
  • FTSE 250

    22,535.29
    +25.17 (+0.11%)
     
  • AIM

    1,242.87
    +4.39 (+0.35%)
     
  • GBP/EUR

    1.1641
    -0.0023 (-0.20%)
     
  • GBP/USD

    1.3900
    -0.0021 (-0.15%)
     
  • BTC-GBP

    24,329.91
    +260.67 (+1.08%)
     
  • CMC Crypto 200

    808.42
    +21.80 (+2.77%)
     
  • S&P 500

    4,266.49
    +24.65 (+0.58%)
     
  • DOW

    34,196.82
    +322.58 (+0.95%)
     
  • CRUDE OIL

    72.95
    -0.35 (-0.48%)
     
  • GOLD FUTURES

    1,782.70
    +6.00 (+0.34%)
     
  • NIKKEI 225

    29,066.18
    +190.95 (+0.66%)
     
  • HANG SENG

    29,288.22
    +405.76 (+1.40%)
     
  • DAX

    15,566.33
    -22.90 (-0.15%)
     
  • CAC 40

    6,618.43
    -12.72 (-0.19%)
     

Visiongain says 'The Global Virus Diagnostic Kits market size is projected to reach US$34.29 billion by 2031'.

·6-min read

Visiongain has published a new report on “Virus Diagnostic Kits Market Report 2021-2031”. Forecasts By Test Type (DFA Tests, Lateral Flow Tests, RT-PCR, Agglutination Assays, Solid-Phase Assays, Others), Application (Influenza, Hepatitis, HIV, Measles/Rubella, Rotavirus, Others); End-User (Laboratories, Hospitals, Home-Care Settings, Academic Institutes), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), PLUS COVID-19 Recovery Scenarios.

This report evaluates the virus testing diagnostic kits market for the period, 2021-2031. ‘The global virus testing diagnostic kits market is estimated to be valued at US$19.9 billion in 2020 and is anticipated to reach US$26.24 billion in 2026. The global market size is further projected to reach US$34.29 billion by 2031’ says Visiongain’s lead analyst.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/virus-testing-kits-market-2021/#download_sampe_div

COVID-19 Impact on Virus Diagnostic Kits Market
At the global level, the COVID-19 epidemic has created an ongoing public health crisis. In the stage of deconfinement and social changes and beyond, diagnostic testing will remain a core pillar. The diagnostic industry is committed to contributing and collaborating with policymakers and other stakeholders to play its part in ensuring that the lives and health of people can be secured as the world continues to tackle the pandemic.

Key Questions Answered by this Report:
• What is the current size of the overall global virus testing diagnostic kits market? How much will this market be worth from 2021 to 2031?
• What are the main drivers and restraints that will shape the overall virus testing diagnostic kits market over the next ten years?
• What are the main segments within the overall virus testing diagnostic kits market? How much will each of these segments be worth for the period 2021 to 2031? How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• What are the largest national markets for the world virus testing diagnostic kits? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2031?
• How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
• Which are the leading companies and what are their activities, results, developments, and prospects?
• What are the main trends that will affect the world virus testing diagnostic kits market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities, and threats for the market?
• How will the global virus testing diagnostic kits market evolve over the forecasted period, 2021 to 2031?
• How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?

Growing Disease Burden
With the growing burden of rare diseases around the world, there has been a rise in the requirement for proper diagnosis as well as full proof treatment positions for various chronic diseases. With increasing awareness regarding symptoms of various terminal illnesses, the diagnosis rates have been improving in developing countries such as China, India, Japan, Brazil, and other southeast Asian countries. Despite the availability of technologically advanced equipment for diagnosis, a small amount of human error has been breaking the process. With this error, a noticeable amount of the patients remains undiagnosed at an early stage making the treatment complicated.

Growing Burden of Influenza to Fuel Demand for Virus Diagnostic Kits Market
Epidemics and pandemics of influenza have an enormous effect on the population and individuals. The weight and extent of the influenza burden vary with the patient's age and underlying health. The disease places a major burden on all people, but in high-risk patients (the elderly and those with some underlying medical conditions) hospitalization and care occur more often; patient populations are rising in size. The need to measure the burden of influenza has been intensified by escalating medical costs. In all such studies, the first step is to assess the prevalence of the disease; this is frequently under-reported for influenza, as the disease can be confused with other viral diseases. In addition to the direct costs of medical care, which derive mainly from absenteeism & loss of work efficiency, the indirect costs of influenza are high. Cost estimates for influenza have shown that in France, the United States, and Germany that indirect costs can be five to 10 times higher than direct costs.

Get Detailed TOC @ https://www.visiongain.com/report/virus-testing-kits-market-2021/#download_sampe_div

Other intangible influenza-related costs include reduced efficiency, which can improve response times, and adverse effects on patients' and their families' quality of life. In this sense, therefore the costs of interventions should be considered. The administration of vaccines is the primary solution to influenza prevention and its related costs. Although vaccinations are broadly successful, the greatest possible benefits are shown in high-risk populations, so vaccination is recommended for high-risk patients, their caregivers, and healthcare workers in several countries.

Competitive Landscape
Some of the companies profiled in the report include Quidel Corporation, F. Hoffmann-La Roche, Alere Inc., Abbott, Thermo Fisher Scientific, Becton, Dickinson and Company, Luminex Corporation, Beckman Coulter, Inc., Cortez Diagnostics, and Bundi International Diagnostics.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, stay informed with this invaluable business intelligence.

To access the data contained in this document please email contactus@visiongain.com
Find more Visiongain research reports on Pharma Industry click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10 year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which we find currently can influence one another. These markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.

Contact:
Sara Peerun
Commercial Director, UK
Visiongain Limited.
Tel: + 44 207 549 9987
Email: sara.peerun@visiongain.com
Web: https://www.visiongain.com/
Follow Us: LinkedIn | Twitter
-
SOURCE Visiongain Limited.



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting